Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT IN WHOLE OR IN PART TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN ELICERA THERAPEUTICS AB. SEE ALSO THE "IMPORTANT INFORMATION" SECTION BELOW. Gothenburg, Sweden June 4, 2021 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that